These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1029 related articles for article (PubMed ID: 36318630)

  • 1. Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women.
    Blakeway H; Amin-Chowdhury Z; Prasad S; Kalafat E; Ismail M; Abdallah FN; Rezvani A; Amirthalingam G; Brown K; Le Doare K; Heath PT; Ladhani SN; Khalil A
    Ultrasound Obstet Gynecol; 2022 Nov; 60(5):673-680. PubMed ID: 36318630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
    Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Sadarangani M; Soe P; Shulha HP; Valiquette L; Vanderkooi OG; Kellner JD; Muller MP; Top KA; Isenor JE; McGeer A; Irvine M; De Serres G; Marty K; Bettinger JA;
    Lancet Infect Dis; 2022 Nov; 22(11):1553-1564. PubMed ID: 35964614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Adverse Reactions, Antibody Patterns, and 12-month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in Pregnancy.
    Cassidy AG; Li L; Golan Y; Gay C; Lin CY; Jigmeddagva U; Chidboy MA; Ilala M; Buarpung S; Gonzalez VJ; Basilio E; Duck M; Murtha AP; Wu AHB; Lynch KL; Asiodu IV; Prahl MK; Gaw SL
    JAMA Netw Open; 2023 Jul; 6(7):e2323405. PubMed ID: 37450302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
    Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
    Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    McClymont E; Atkinson A; Albert A; Av-Gay G; Andrade J; Barrett J; Bogler T; Boucoiran I; Castillo E; D'Souza R; El-Chaâr D; Fadel S; Fell DB; Korchinski I; Kuret V; Ogilvie G; Poliquin V; Sadarangani M; Scott H; Snelgrove JW; Tunde-Byass M; Money D;
    Vaccine; 2023 Nov; 41(48):7183-7191. PubMed ID: 37865598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Flaxman A; Marchevsky NG; Jenkin D; Aboagye J; Aley PK; Angus B; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Cicconi P; Clutterbuck EA; Davies S; Dejnirattisai W; Dold C; Ewer KJ; Folegatti PM; Fowler J; Hill AVS; Kerridge S; Minassian AM; Mongkolsapaya J; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Sheehan E; Smith H; Snape MD; Song R; Woods D; Screaton G; Gilbert SC; Voysey M; Pollard AJ; Lambe T;
    Lancet; 2021 Sep; 398(10304):981-990. PubMed ID: 34480858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.
    Prabhu M; Yang YJ; Johnston CD; Murphy EA; Ketas TJ; Diaz-Tapia R; Jurkiewicz M; Racine-Brzostek S; Mohammed I; Sukhu AC; Singh S; Forlenza K; Iyer S; Yee J; Eng D; Marks K; Zhao Z; Klasse PJ; Permar S; Moore JP; Riley LE
    Am J Obstet Gynecol MFM; 2023 Feb; 5(2):100796. PubMed ID: 36334723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network.
    Bettinger JA; Irvine MA; Shulha HP; Valiquette L; Muller MP; Vanderkooi OG; Kellner JD; Top KA; Sadarangani M; McGeer A; Isenor JE; Marty K; Soe P; De Serres G;
    Clin Infect Dis; 2023 Mar; 76(6):1088-1102. PubMed ID: 36310514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 IgG Is Present in the Amniotic Fluid of both Infected and Vaccinated Women at Second Trimester of Pregnancy: A Cohort Study.
    La Fauci L; Cavaliere R; Romeo P; Alibrandi A; Ferlazzo G; D'Anna R; Corrado F
    Fetal Diagn Ther; 2023; 50(6):415-421. PubMed ID: 37433286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
    Abu Shqara R; Frank Wolf M; Mikhail Mustafa S; Sgayer I; Assulyn T; Abu Zraki A; Askhar Majadla N; Rechnizter H; Shehadeh M; Fleisher Sheffer V; Bordeynik-Cohen M; Yakir O; Lowenstein L; Sela E; Edelstein M; Dror AA
    Am J Perinatol; 2024 May; 41(S 01):e1935-e1943. PubMed ID: 37164317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth.
    Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Lahav Sher M; Barsha H; Shalabna E; Zolotarevsky A; Lavie O; Kedar R; Riskin-Mashiah S
    Eur J Obstet Gynecol Reprod Biol; 2022 Jul; 274():148-154. PubMed ID: 35653903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.
    Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Sher ML; Gruber M; Marom I; Zolotarevsky A; Lavie O; Damti A; Zilberlicht A; Bardicef M; Kedar R
    JAMA Pediatr; 2022 Mar; 176(3):290-295. PubMed ID: 34932066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination in pregnancy: early experience from a single institution.
    Trostle ME; Limaye MA; Avtushka V; Lighter JL; Penfield CA; Roman AS
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100464. PubMed ID: 34411758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.